MarkChristopherGenoveseMD

Rheumatoid Arthritis & Related, Vasculitis

SVP Immunology Clinical Development Eli Lilly and Company Professor, Medicine Emeritus Active - Immunology & Rheumatology, Stanford University Medical Center

Join to view full profile

Dr. Genovese is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Genovese's full profile

Already have an account?

Office
300 Pasteur Dr
Palo Alto, CA 94305
Phone+1 650-723-6961

Fax+1 650-725-8418

Summary

Dr. Mark Genovese is a rheumatologist in Palo Alto, CA and is affiliated with multiple hospitals in the area, including Stanford Health Care and VA Palo Alto Health Care System. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 25 years. He specializes in rheumatoid arthritis & related and vasculitis and is experienced in severity of illness index.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Rheumatology, 1996 - 1998
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1992 - 1995
Johns Hopkins University School of MedicineClass of 1992

Certifications & Licensure

CA State Medical License 1993 - 2026
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Fellow (FACP) American College of Physicians, 2003
Fellow (FACR) American College of Rheumatology

Clinical Trials

A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis Start of enrollment: 2005 Jun 01
Completed
Phase 2
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis Start of enrollment: 2005 Dec 01
Terminated
Phase 2
Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA) Start of enrollment: 2008 Nov 01
Terminated
Phase 4
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients Start of enrollment: 2010 Mar 01
Completed
Phase 2, Phase 3
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA Start of enrollment: 2010 Sep 01
Withdrawn
Phase 2
Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee Start of enrollment: 2012 May 01
Completed
Phase 2
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2013 Jun 27
Completed
Phase 3
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease Start of enrollment: 2016 Jun 06
Completed
Phase 3
Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA) Start of enrollment: 2018 Mar 06
Completed
Not Applicable
Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis Start of enrollment: 2019 Sep 03
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

306 citations
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis w...
Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese, Eun Bong Lee, Keith S. Kanik
Arthritis and Rheumatism. 2012-03-01
338 citations
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Joel M. Kremer, Zhanguo Li, Stephen B. Hall, Roy Fleischmann, Mark C. Genovese
Annals of Internal Medicine. 2013-08-20
501 citations
Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expressi...
Eric J. Kunkel, James Campbell, Guttorm Haraldsen, Junliang Pan, Judie Boisvert
The Journal of Experimental Medicine. 2000-09-05

Journal Articles

ABT‐122, a Bispecific DVD‐Immunoglobulin Targeting TNF– and IL‐17A, in RA with Inadequate Response to Methotrexate: A Randomized, Double‐Blind Study
Michael E Weinblatt, Mark C Genovese, Jacob A Aelion, Arthritis & Rheumatology

Press Mentions

Studies Probe Treating Rheumatoid Arthritis with Vagus Nerve StimulationJune 14th, 2021
Gilead Inks Deal with Novo Nordisk to Collaborate on NASH Treatment Leading to Phase 2b Study Using Cilofexor and FirsocostatMarch 19th, 2021
Gilead and Novo Nordisk Expand NASH Clinical CollaborationMarch 18th, 2021
Join now to see all

Grant Support

Clinical Trial: Rituximab With Or Without Methotrex In Psoriatic Arthritis And PNational Center For Research Resources2008
Study Of Taci-Fc5 In Patients With Systemic Lupus Erythematosus (SLE)National Center For Research Resources2007
Fontolizumab In Subjects With Active Rheumatoid ArthritisNational Center For Research Resources2007
Tumor Necrosis Factor-Alpha Inhibition (ADALIMUMAB) In OsteoarthritisNational Center For Research Resources2006–2007
Study Of Taci-Fc5 Administered To Patients With Systemic Lupus ErythematosusNational Center For Research Resources2005–2006
Monoclonal Anti-Blys Antibody In Subjects With Systemic Lupus ErythematosusNational Center For Research Resources2005–2006